Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
EtiraRx General Information
EtiraRx develops next-generation small molecule therapies aimed at overcoming tumor heterogeneity—the main barrier to durable responses in cancer treatment. The company’s mission centers on making untreatable, therapy-resistant cancers manageable by creating smarter medicines. No published clinical results are available as of now
Contact Information
Drug Pipeline
ERX-315
Phase 1Key Partnerships
EtiraRx Funding
No funding data available
To view EtiraRx's complete valuation and funding history, request access »